Investigational Treatment for Solitary Plasmacytoma of the Bone

Trial ID:
IRB-16-6883
Anuj Mahindra, MD
This study will investigate if using a combination of cancer drugs (lenalidomide, ixazomib, dexamethasone and zoledronic acid) along with radiation therapy is better, the same, or worse for treating solitary plasmacytoma of the bone compared to the usual treatment of radiation therapy and zoledronic acid alone.

Inclusion Criteria

  • Be 18 years of age or older
  • Be willing and able to undergo bone marrow aspiration and biopsy at the beginning and during the study

Exclusion Criteria

  • Have had other cancers within 5 years (certain previously treated skin cancers are allowed)
  • Be pregnant or nursing

Additional Info

  • Solitary plasmacytoma of the bone is usually treated with radiation therapy and cancer drugs are not normally used.

Contact Info: